Using network and functional enrichment clustering analyses to find therapeutic targets for breast cancer: The role of cyclin-dependent kinase 2

被引:0
|
作者
Valenzuela, Luis [1 ]
Assar, Rodrigo [1 ,2 ,3 ]
机构
[1] Univ Chile, ICBM Inst Biomed Sci, Sch Med, ZA-1027 Santiago, Chile
[2] Gerosci Ctr Brain Hlth & Metab GERO, Santiago, Chile
[3] Proyecto Chile Genom, Santiago, Chile
关键词
breast cancer biomarkers; functional enrichment analysis; gene expression clustering; gene network analysis; PREDICTIVE FACTORS; GENE; RETINOBLASTOMA; EXPRESSION; GROWTH; MYB; PROMOTER; PCNA;
D O I
10.1002/mma.4788
中图分类号
O29 [应用数学];
学科分类号
070104 ;
摘要
Population aging is rapidly increasing in developing countries; thus, covering medical needs for breast cancer diagnosis and treatment is a priority in Latin America. We describe an approach for integrating differential expression analysis, biological pathway enrichment, in silico transcription-binding sites and network topology, to find key genes that may be used as biomarkers or therapeutic targets. This approach is based on publicly available data from microarrays of the MCF-7 breast cancer cell line treated with estrogen. We found significant estrogen-responsive genes, which were used as nodes to construct networks based on protein-protein interactions reported in the literature. Then, we conducted a topology analysis of the networks, revealing the most-connected nodes, ie, those responsible for maintaining the network structure corresponding to genes with well-acknowledged functions in G1/S cell cycle transition, such as cyclin-dependent kinase 2 (CDK2), which has been proposed as a therapeutic target in classical biochemical studies. In addition, analyses of biological pathway enrichment and in silico transcription-binding sites support the biological meaning and importance of these key genes and help to decide the best target genes. Therefore, we postulate that the integrative bioinformatics approach shown here, unlike the classical bioinformatics approach that only includes differentially expressed genes and enriched biological pathways, can be applied as an approach for finding novel biomarkers and/or therapeutic target genes for nonresponsive treatments.
引用
收藏
页码:8514 / 8527
页数:14
相关论文
共 50 条
  • [31] Thromboembolic disease associated with cyclin-dependent kinase inhibitors in patients with breast cancer
    Lopez Robles, J.
    Adoamnei, E.
    Cacho Lavin, D.
    Diaz PedRoche, C.
    Coma Salvans, E.
    Pamies Ramon, M. I.
    Verdejo, F. J. G.
    Cejuela, M.
    Garcia-Adrian, S.
    Portero, B. O.
    Garrido Fernandez, A.
    Salvador Coloma, C.
    Mendiola, J.
    Munoz Martin, A. J.
    Sanchez Canovas, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1117 - S1117
  • [32] Therapeutic efficacy of cyclin-dependent kinase inhibition in combination with ionizing radiation for lung cancer
    Chen, Jenny Ling-Yu
    Pan, Chun-Kai
    Lin, Li-Cheng
    Tsai, Ching-Yi
    Kuo, Ching-Ying
    Huang, Yu-Sen
    Lin, Yu-Li
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2023, 99 (08) : 1257 - 1266
  • [33] Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes - Retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets
    Songia, S
    Mortellaro, A
    Taverna, S
    Fornasiero, C
    Scheiber, EA
    Erba, E
    Colotta, F
    Mantovani, A
    Isetta, AM
    Golay, J
    JOURNAL OF IMMUNOLOGY, 1997, 158 (08): : 3987 - 3995
  • [34] Cyclin-dependent kinase 4 and 6 inhibitors at the crossroads: the combinational therapeutic strategies in breast cancer-a narrative review
    Yang, Yiqi
    Zhu, Sha
    Fu, Ziyi
    Sun, Chunxiao
    Yang, Fan
    Zeng, Tianyu
    Hua, Yijia
    Bao, Shengnan
    Gao, Xian
    Huang, Xiang
    Li, Wei
    Yin, Yongmei
    TRANSLATIONAL BREAST CANCER RESEARCH, 2021, 2
  • [35] Association of cyclin-dependent kinase inhibitor 2A/B with increased risk of developing breast cancer
    Seifi, Sima
    Pouya, Farzaneh
    Rahmani, Mahsa
    Mehramiz, Mehrane
    Rastgar-Moghadam, Azam
    Gharib, Masoumeh
    Rahmani, Farzad
    Shahidsales, Soodabeh
    Hassanian, Seyed Mahdi
    Khazaei, Majid
    Dadjoo, Parisa
    Parvin, Seyede Sara
    Yazdinezhad, Yeganeh
    Parizadeh, Seyed Mohammad Reza
    Ferns, Gordon A.
    Fathi, Mehdi
    Avan, Amir
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (06) : 5141 - 5145
  • [36] Cyclin-dependent kinase 2 regulates androgen receptor activity in estrogen receptor negative breast cancer
    Proctor, Luke A.
    Hanson, Adrienne R.
    Butler, Miriam S.
    Tilley, Wayne D.
    Moore, Nicole L.
    MOLECULAR CANCER RESEARCH, 2013, 11
  • [37] Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells
    Harwell, RM
    Mull, BB
    Porter, DC
    Keyomarsi, K
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (13) : 12695 - 12705
  • [38] Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib
    Dorota Kwapisz
    Breast Cancer Research and Treatment, 2017, 166 : 41 - 54
  • [39] A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer
    Bilgin, Burak
    Sendur, Mehmet A. N.
    Dede, Didem Sener
    Akinci, Muhammed Bulent
    Yalcin, Bulent
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (09) : 1559 - 1569
  • [40] Cyclin-dependent kinase 15 upregulation is correlated with poor prognosis for patients with breast cancer
    Zhang, Xiquan
    Wang, Qin
    Luo, Yijun
    Song, Meijiao
    Zhou, Zhiyong
    Zeng, Lin
    Hu, Meng
    Yang, Chuyan
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (06)